...
首页> 外文期刊>Circulation. Cardiovascular interventions >Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: Analysis from the national cardiovascular data registry
【24h】

Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: Analysis from the national cardiovascular data registry

机译:在经皮冠状动脉介入治疗术前出血风险范围内比较比伐卢定和radial动脉通路:来自国家心血管数据注册中心的分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background-Bleeding is a common, noncardiac, preventable complication of percutaneous coronary intervention. We compared the relative safety of radial access and bivalirudin in percutaneous coronary intervention. Methods and Results-From CathPCI Registry, we determined the association between the site of arterial access, bivalirudin, and periprocedural bleeding rates in 501 017 patients. Radial access patients receiving heparin (radial group) were compared with those receiving bivalirudin (radial combination group). Femoral access patients who had bivalirudin and a vascular closure device served as a reference group (femoral group). An inverse probability weighting analysis incorporating propensity scores was used to compare groups. The overall rate of bleeding was 2.59%. It was 2.71% in the femoral group, 2.5% in the radial group, and 1.82% in the radial combination groups (P<0.001). When compared with femoral group, the adjusted odds ratio for bleeding was significantly lower for patients with radial combination group (odds ratio, 0.79; 95% confidence interval, 0.72-0.86), but not for radial group (odds ratio, 0.96; 95% confidence interval, 0.88-1.05), unless patients treated with IIb/IIIa were excluded (radial group-IIb/IIIa odds ratio, 0.84; 95% confidence interval, 0.75-0.94).The number needed to treat to prevent 1 bleeding event with radial combination group was 138, whereas the number needed to treat to prevent 1 bleeding event in high-bleeding risk patients was 68. Conclusions-In this observational analysis, the combination of bivalirudin and radial access was associated with reduced bleeding event rate. This benefit was present across the entire spectrum of preprocedural risk of bleeding, with or without exposure to IIb/IIIa inhibitors. These data support an adequately powered randomized trial comparing bleeding avoidance strategies.
机译:背景出血是经皮冠状动脉介入治疗的常见,非心脏,可预防的并发症。我们比较了经皮冠状动脉介入治疗中radial动脉入路和比伐卢定的相对安全性。方法和结果-从CathPCI注册中心,我们确定了501 017例患者的动脉通路部位,比伐卢定和术中出血率之间的相关性。将接受肝素的放射治疗患者(放射治疗组)与接受比伐卢定的放射治疗患者(放射治疗联合组)进行比较。具有比伐卢定和血管闭合装置的股骨入路患者作为参考组(股骨组)。结合倾向得分的逆概率加权分析用于比较各组。总体出血率为2.59%。股骨组为2.71%,the骨组为2.5%,the骨联合组为1.82%(P <0.001)。与股骨组相比,放射联合组患者的调整后出血几率显着降低(优势比为0.79; 95%置信区间为0.72-0.86),而radial骨联合组则无此优势(优势比为0.96; 95%)置信区间为0.88-1.05),除非排除用IIb / IIIa治疗的患者(放射治疗组IIb / IIIa的优势比为0.84; 95%置信区间为0.75-0.94)。放射联合治疗组为138人,而预防高出血风险患者发生1次出血事件所需的治疗数目为68。结论-在这项观察性分析中,比伐卢定和放射治疗相结合可降低出血事件发生率。无论是否暴露于IIb / IIIa抑制剂,这种益处在整个术前出血风险范围内均存在。这些数据支持一项比较有力的随机试验,比较了避免出血的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号